WO2026133279 - FUSED TRICYCLIC HETEROCYCLES HAVING ACTIVITY AGAINST HIV INFECTION
National phase entry is expected:
Publication Number
WO/2026/133279
Publication Date
25.06.2026
International Application No.
PCT/IB2025/063248
International Filing Date
19.12.2025
Title **
[English]
FUSED TRICYCLIC HETEROCYCLES HAVING ACTIVITY AGAINST HIV INFECTION
[French]
HÉTÉROCYCLES TRICYCLIQUES FUSIONNÉS AYANT UNE ACTIVITÉ CONTRE L'INFECTION PAR LE VIH
Applicants **
VIIV HEALTHCARE UK (NO.7) LIMITED
SHIONOGI & CO., LTD.
Inventors
NAIDU, B. Narasimhulu
TAODA, Yoshiyuki
BOWSHER, Michael S.
Priority Data
63/736,760
20.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4635 | |
| EPO | Filing, Examination, Granting | 27470 | |
| Japan | Filing, Examination, Granting | 2907 | |
| South Korea | Filing, Examination, Granting | 3529 | |
| USA | Filing, Examination, Granting | 14740 |
Total:
53,281
Contact Us
Abstract[English]
The present disclosure relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The present disclosure also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in prevention and treatment of HIV infection in a human.[French]
La présente divulgation concerne des composés de formule (I) et leurs sels pharmaceutiquement acceptables. La présente divulgation concerne également des compositions pharmaceutiques comprenant de tels composés et des méthodes d'utilisation de tels composés dans la prévention et le traitement de l'infection par le VIH chez l'être humain.